Compare ELTK & PDSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELTK | PDSB |
|---|---|---|
| Founded | 1970 | 2005 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.3M | 49.5M |
| IPO Year | 1997 | N/A |
| Metric | ELTK | PDSB |
|---|---|---|
| Price | $9.20 | $0.93 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 5.7K | ★ 686.2K |
| Earning Date | 03-10-2026 | 11-13-2025 |
| Dividend Yield | ★ 2.02% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.17 | N/A |
| Revenue | ★ $49,310,000.00 | N/A |
| Revenue This Year | $18.60 | N/A |
| Revenue Next Year | $9.04 | N/A |
| P/E Ratio | $54.51 | ★ N/A |
| Revenue Growth | ★ 2.54 | N/A |
| 52 Week Low | $7.65 | $0.70 |
| 52 Week High | $12.19 | $2.20 |
| Indicator | ELTK | PDSB |
|---|---|---|
| Relative Strength Index (RSI) | 54.03 | 50.84 |
| Support Level | $8.64 | $0.92 |
| Resistance Level | $9.41 | $1.02 |
| Average True Range (ATR) | 0.24 | 0.08 |
| MACD | 0.11 | 0.00 |
| Stochastic Oscillator | 64.06 | 42.40 |
Eltek Ltd is engaged in the technology business sector that manufactures and supplies technologically new custom-made circuitry solutions. It manufactures, markets, and sells custom-made printed circuit boards (PCBs), including high-density interconnect, flex-rigid and multi-layered boards. The Company markets its products mainly to the medical technology, defense and aerospace, industrial, telecom, and networking equipment industries. Its geographic areas are Israel, North America, the Netherlands, India, and Others. It generates the majority of its revenue from Israel.
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.